Year 2000 and before:
• Pegasus Pharmaceuticals Group Inc. ("Pegasus") established a subsidiary company, Panagin Pharmaceuticals Inc., which is committed to the research and development of selective metabolite compound drug containing ginsenosides, and the novel drug applications around the world.
• Preliminary studies from the University of British Columbia (UBC), Canada showed that ginsenoside Rh2 is cytotoxic to cancer cells without toxicity and maybe the ideal anti-cancer drug candidate.
• In order to precisely develop the ginsenosides compound drug, Pegasus established the proprietary Selective Metabolites Compound Drug (SMCD) technology platform.
• Pegasus' Chief Scientist Dr. William Jia applied patent for "Ginsenoside Chemotherapy" in Canada (CA2,307,393) and U.S. (60/204,785).

1999:
• Pegasus reached an agreement with the University of British Columbia (UBC), Canada to collaborate in the research project of the pharmacological activities of ginsenosides (Saponins) and aglycone ginsenosides (Sapogenins).

1998:
• Company founder Mr. Winter Huang changed the name of "Hope Clinic Inc." to "Pegasus Pharmaceuticals Group Inc." and transferred his extraction technologies of dammarane-type aglycone ginsenosides to the company.
• Early animal studies showed that Pegasus' novel botanical compound can inhibit tumor growth.
• Pegasus Pharmaceuticals (Dalian) Co., Ltd. in collaboration with the Norman Bethune Medical University, China (now part of the Jilin University), applied the Chinese patent for "20(s)-ginsenosides-Rh2 Production Process, Pharmaceutical Composition and Its Uses" (CN98100297).

1997:
• China Huayuan Inc. (Canada) is closed and Hope Clinic Inc. is set up.

1996:
• China Huayuan Inc. (Canada) and the University of British Columbia (UBC), Canada collaborated in research of the pharmacological activities of ginsenosides Rh2.

1993:
• Mr. Winter Huang invented the proprietary extraction technologies of ginsenosides Rh2, and founded the China Huayuan Inc. (Canada) in Vancouver, Canada.